All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ciliatech SAS secured $3.87 million in series A funding to continue developing its second-generation implant to treat open-angle glaucoma. This round was led by its historical shareholders, including BNP Development SAS, Kreaxi SAS and individual investor Bernard Chauvin. “With this additional money, we can continue clinical trials to obtain the CE mark,” Olivier Benoit, co-founder and CEO of Ciliatech SAS told BioWorld.
Therini Bio Inc. has closed a US$36 million series A financing round that will support its work on developing fibrin-targeted therapies for diseases driven by chronic inflammation, including Alzheimer’s disease, multiple sclerosis and retinal diseases such as diabetic macular edema.
Pharmaessentia Corp. raised $462.7 million in a global depositary receipt (GDR) offering on the Luxembourg Stock Exchange that marks the largest global health care GDR offering so far this year. The capital raise “reflects confidence in the market opportunity for our approved product and the potential of our pipeline,” said Pharmaessentia founder and CEO Ko-Chung Lin.
Orbital Therapeutics Inc. raised $270 million in a series A round to fund a big push into the next generation of mRNA-based therapies. The Cambridge, Mass.-based firm is building out a comprehensive RNA platform from which it will launch programs in oncology, autoimmune disease and indications involving protein replacement approaches.
RSS
